首页> The lancet. HIV> Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Elizabeth D,Lowenthal

第一单位： The Children's Hospital of Philadelphia, PA, USA; University of Pennsylvania Perelman School of Medicine, PA, USA. Electronic address: lowenthale@chop.edu.

作者： Elizabeth D,Lowenthal ^[1] ; Jennifer,Chapman ^[2] ; Kristin,Baltrusaitis ^[3] ; Grace,Kovic ^[3] ; Sanjna,Merchant ^[4] ; Kaleb,Branch ^[5] ; Chermiqua,Tsosie ^[2] ; Martina Zapata,Vaca ^[2] ; Barbara,Heckman ^[6] ; Rodica M,Van Solingen-Ristea ^[7] ; Conn M,Harrington ^[8] ; Dwight E,Yin ^[9] ; Ellen,Townley ^[9] ; Michael,Whitton ^[10] ; Allison L,Agwu ^[11] ; Christiana,Smith ^[12] ; Mary E,Paul ^[13] ; Avy,Violari ^[14] ; Evette,Moodley ^[15] ; Maxensia,Owor ^[16] ; Kulkanya,Chokephaibulkit ^[17] ; Samantha,Fry ^[18] ; Jennifer,Jao ^[19] ; Charles D,Mitchell ^[20] ; Sarah,Buisson ^[10] ; Andi,Ace ^[6] ; Irina,Kolobova ^[8] ; Carolyn,Bolton-Moore ^[21] ; Aditya H,Gaur ^[22] ; IMPAACT 2017 Collaborators ; IMPAACT 2017 Team

作者单位： The Children's Hospital of Philadelphia, PA, USA; University of Pennsylvania Perelman School of Medicine, PA, USA. Electronic address: lowenthale@chop.edu. ^[1] The Children's Hospital of Philadelphia, PA, USA. ^[2] Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, MA, USA. ^[3] University of Pennsylvania College of Arts and Sciences, PA, USA. ^[4] University of Pennsylvania Perelman School of Medicine, PA, USA. ^[5] Frontier Science Foundation, NY, USA. ^[6] Johnson & Johnson, Beerse, Belgium. ^[7] Viiv Healthcare, NC, USA. ^[8] National Institute of Allergy and Infectious Diseases Division of AIDS, National Institutes of Health, MD, USA. ^[9] FHI 360 IMPAACT Operations Center, NC, USA. ^[10] Johns Hopkins University School of Medicine, MD, USA. ^[11] University of Colorado School of Medicine, Aurora, CO, USA. ^[12] Baylor College of Medicine, Houston, TX, USA. ^[13] Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. ^[14] Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, South Africa. ^[15] MU-JHU Care Limited, Kampala, Uganda. ^[16] Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. ^[17] FAMCRU, Western Cape, South Africa. ^[18] Northwestern University Feinberg School of Medicine, IL, USA. ^[19] University of Miami Miller School of Medicine, FL, USA. ^[20] Centre for Infectious Disease Research in Zambia-University of Alabama Birmingham, Lusaka, Zambia. ^[21] St Jude Children's Research Hospital, Memphis, TN, USA. ^[22]

医学主题词人类(Humans);青少年(Adolescent);女(雌)性(Female);男(雄)性(Male);HIV感染(HIV Infections);HIV-1(HIV-1);抗HIV药(Anti-HIV Agents);二酮哌嗪类(Diketopiperazines);吡啶酮类(Pyridones);注射, 肌肉内(Injections, Intramuscular);生活质量(Quality of Life);治疗结果(Treatment Outcome);泰国(Thailand);乌干达(Uganda)

DOI 10.1016/S2352-3018(25)00241-3

PMID 41547358

发布时间 2026-06-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The lancet. HIV

2026年13卷2期

e95-e103页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

The lancet. HIV

2026年13卷2期

e95-e103页

检索历史清除

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

The lancet. HIV

相似文献

同项目论文

The lancet. HIV

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

The lancet. HIV

相似文献

同项目论文

The lancet. HIV

相关期刊

检索历史清除